Wei, AH, Reyner, JE, Garciaz, S, Aldoss, I, Piérola, A, Allred, A, Dominguez, JMA, Barreyro, L, Bories, P, Daskalakis, N, Porta, MGD, Döhner, H, D'Souza, A, Dugan, J, Fathi, A, Fedele, P, Ferrante, L, Kobos, R, Gaj, S, Diaz, AG, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Trancucci, D, Bamidele, T, Jentzsch, M, Kantarjian, H, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, O'Nions, J, Packman, K, Papayannidis, C, Récher, C, Roellig, C, Salamero, O, Nagarajahastri, P, Sauer, T, Searle, E, Tovar, N, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Platzbecker, U. Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax plus Azacitidine (VEN plus AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Borrell-Pichot, M, Lozano, A, Granell, E, Caballero, A, Briones-Mejide, J, Caballero-Avila, M, Vidal-Jordana, A, Querol, L, Mart n-Aguilar, L. Regression of pre-existing white matter hyperintensities after CD19 CAR Tcell induced ICANS: A case series. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

Cortés-Bullich, A, Guijarro, F, Jiménez-Vicente, C, Bataller, A, Martínez-Roca, A, Triguero, A, Guerra, ML, Castaño-Diez, S, Oñate, G, Díaz-Beyá, M, Pich-Roselló, O, Esteve, J. RNA-Seq analysis of the tumor microenvironment reveals prognostic subgroups in Acute Myeloid Leukemia with myelodysplasia-related gene mutations. ANNALS OF HEMATOLOGY. 2025; 104(1)DOI:. PMID:. IF:2.400(Q2/5D).

Bastos-Oreiro, M, Iacoboni, G, Garcés, VN, Caballero, AC, Martínez, N, Delgado, J, Balaguer, A, Kwon, M, de Villambrosia, S, Hernani, R, Jimenez-Ubieto, A, Bailen, R, Zaberio, I, García-Sancho, A, Barba, P. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Hemasphere. 2025; 9(2)DOI:10.1002/hem3.70077. PMID:39906687. IF:14.600(Q1/1D).

Ramos-Pachón A, Rodríguez-Luna D, Martí-Fàbregas J, Millán M, Bustamante A, Martínez-Sánchez M, Serena J, Terceño M, Vera-Cáceres C, Camps-Renom P, Prats-Sánchez L, Rodríguez-Villatoro N, Cardona-Portela P, Urra X, Solà S, Del Mar Escudero M, Salvat-Plana M, Ribó M, Abilleira S, Pérez de la Ossa N, Silva Y. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial.. JAMA Neurology. 2023; 80(10)DOI:10.1001/jamaneurol.2023.2754. PMID:37603325. IF:20.900(Q1/1D).